ADC Therapeutics S.A.

NYSE:ADCT

Biotechnology

Healthcare
$1.37 -1.35%

-$0.02 today

Market cap
$192.71M
Beta
1.77
P/E (TTM)
-1.2
EPS (TTM)
-$0.89
52W Low $0.78High $4.98

Volume 1.17M

Average 1.68M

ADCT Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

ADC Therapeutics S.A.NYSE: ADCT

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation grows, but more slowly than its trailing trend

Q1 FY2026 stock-based compensation of $2.44M rose 0.9% year over year, behind the +26.4% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 60.1% from the prior quarter. Over 3 fiscal years it compounded at -48.5% a year.

Context

  • Stock-based compensation amounted to 8.5% of revenue in FY2025, down 0.8 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +0.9% toward the trailing-twelve-month pace of +26.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.44M-60.1% QoQ
Last fiscal yearDec 2025
$6.91M+5.1% YoY
LTMMar 2026
$12.63M+26.4% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.9%——
1 year+5.1%——
3-year CAGR-48.5%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
6.91M USD
Year-over-year change
+5.1%
4-year CAGR
-41.9%

Stock-Based Compensation vs competitors

How ADCT compares with its peers on the latest reported figures

  • ADCT's LTM Mar 2026 stock-based compensation of $12.63M is the 5th largest of the 10 companies compared; the peer median is $12.55M.
  • Its year-over-year change of +26.4% is the highest of 10, against a peer median of -7.4%.
  • Stock-based compensation amounts to 16.0% of revenue for ADCT, versus a peer median of 27.0%.
ADCT Competitors Peer median
Stock-Based Compensation for ADCT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALMSAlumis Inc. Common StockLTM Jun 2026$36.4M -7.4%+94.0%492.0%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$27.96M -33.3%+53.3%—
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$19.48M -28.2%+8.7%22.1%
AUTLAutolus Therapeutics plcLTM Mar 2026$15.14M -5.7%+6.3%16.3%
ADCTADC Therapeutics S.A.LTM Mar 2026$12.63M +26.4%-48.5%16.0%
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026$12.55M +2.5%+2.8%18.0%
QSIQuantum-Si incorporatedLTM Mar 2026$10.98M +14.3%-1.3%592.7%
OMEROmeros CorporationLTM Mar 2026$5.74M +13.3%—58.0%
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026$4.71M -8.3%+3.5%31.8%
BCYCBicycle Therapeutics plcLTM Mar 2026$2.68M -107.0%+13.8%4.2%
Peer median (excluding ADCT) $12.55M-7.4%+7.5%27.0%

Competitors are the stored peer set for ADCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(230.03M)(157.13M)(240.05M)(157.85M)(142.62M)
Depreciation & Amortization2.63M5.74M3.27M3.28M1.88M
Deferred Income Tax(26.05M)037.1M00
Stock-Based Compensation60.48M50.64M13.5M6.57M6.91M
Change in Working Capital(15.71M)(49.04M)44.27M3.83M(25.36M)
Accounts Receivables(30.22M)(42.75M)47.79M4.77M(8.79M)
Inventory(3.02M)(9.65M)(5.71M)(3.73M)(2.38M)
Accounts Payables6.8M310K3.17M2.46M(9.04M)
Other Working Capital10.73M3.37M(979K)321K(5.15M)
Other Non-Cash Items(24.7M)11.48M23.23M20.34M18.02M
Operating Cash Flow(233.38M)(138.31M)(118.69M)(123.84M)(141.17M)
Capital Expenditures(6.38M)(687K)(3.22M)(867K)(264K)
Acquisitions (Net)0000659K
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(3.24M)0000
Investing Cash Flow(6.67M)(687K)(3.22M)(867K)395K
Debt Repayment48.61M(2.71M)000
Common Stock Issued00060.51M152.46M
Common Stock Repurchased0(1.32M)000
Dividends Paid00000
Other Financing Activities218.78M3.13M73.88M36.55M(1.51M)
Financing Cash Flow267.39M(897K)73.88M97.05M150.95M
Effect of Forex Changes6K(208K)184K(83K)305K
Net Change in Cash27.35M(140.1M)(47.84M)(27.73M)10.47M
Free Cash Flow(239.75M)(139M)(121.9M)(124.7M)(141.44M)

ADC Therapeutics S.A.

NYSE:ADCT

Intrinsic Alpha fair value

Locked

Current Price

$1.37

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.